We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now .  Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is one of the best up and coming stocks on our list.

TheFly reported on June 25 that JPMorgan adjusted its price target for LXEO, lowering it to $9 from $12 while maintaining an Overweight rating on the shares. The firm stated that the revision was based on an updated valuation model incorporating the company's latest developments and recent updates.

Separately, on June 15, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) announced the completion of the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006, its gene therapy candidate targeting Friedreich's ataxia cardiomyopathy. The finalized study design is intended to support a potential FDA biologics license application submission under the accelerated approval pathway in 2028. The FDA confirmed that no additional nonclinical bridging studies are required, allowing LXEO to proceed with patient dosing using its optimized manufacturing process. The company expects SUNRISE-FA 2 topline data in the second half of 2027, followed by a potential BLA submission in the first half of 2028.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage biotech company developing AAV-based gene therapies for genetic cardiovascular diseases and APOE4-associated Alzheimer's disease.

While we acknowledge the potential of LXEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News .